Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies

Cytotherapy

Volumn 3, Issue 4, 2001, Pages 253-260

  Gurman G ^a   Arat, Mutlu ^a   Ilhan, O ^a   Konuk, N ^a   Beksac M ^a   Celebi H ^a   Ozcan M ^a   Arslan, O ^a   Ustun C ^a   Akan, H ^a   Uysal, A ^a   Koc H ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Allogeneic hematopoietic cell transplantation; Donor leukocyte infusions; Graft versus malignancy effect; Mixed chimerism; Non Myeloablative conditioning

Indexed keywords

ACICLOVIR; BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; T LYMPHOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ALLOTRANSPLANTATION; ARTICLE; BLOOD DONOR; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CHIMERA; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CLINICAL ARTICLE; DEATH; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKEMIA; LEUKOCYTE TRANSFUSION; LYMPHOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOZYGOTIC TWINS; PROPHYLAXIS; PUVA; SEPSIS; T LYMPHOCYTE; THROMBOCYTE TRANSFUSION; TOXICITY; TREATMENT FAILURE;

EID: 18444381727     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532401317070880     Document Type: Article

References (20)

1. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion
2. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
3. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
4. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
5. Evidence of cytogenetic and molecular remission by allogeneic cells after imunosuppressive therapy alone
6. Transplant-lite: Induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
7. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect
8. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice
9. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lymphoma
10. Outpatient PBSC allografts using immunosuppression with low dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant
11. Epstein-Barr virus associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation
12. Invasive fungal infections following reduced conditioning for matched allogeneic stem cell transplantation (alloSCT)
13. Non-myeloablative conditioning regimen in allogeneic peripheral blood stem cell transplantation (alloPBSCT) for high risk hematologic malignancies - Preliminary results
14. The combined effect of total body irradiation (TBI) and cyclosporine A (CsA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation
15. A non-myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GvHD
16. Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukaemia undergoing BMT preconditioned with a new, non-myeloablative drug combination
17. Mixed lymphohaematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
18. Hematopoietic stem cell allografts using a nonmyeloablative conditioning regimen can be safely performed on an outpatient basis: Report of four cases
19. Comparison of single dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukaemia
20. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions